KARUNA THERAPEUTICS INC (KRTX) Fundamental Analysis & Valuation

NASDAQ:KRTX • US48576A1007

Current stock price

329.83 USD
+0.09 (+0.03%)
At close:
329.83 USD
0 (0%)
After Hours:

This KRTX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. KRTX Profitability Analysis

1.1 Basic Checks

  • In the past year KRTX has reported negative net income.
  • In the past year KRTX has reported a negative cash flow from operations.
  • KRTX had negative earnings in each of the past 5 years.
  • KRTX had a negative operating cash flow in each of the past 5 years.
KRTX Yearly Net Income VS EBIT VS OCF VS FCFKRTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 -100M -200M -300M -400M

1.2 Ratios

  • With a decent Return On Assets value of -32.46%, KRTX is doing good in the industry, outperforming 69.32% of the companies in the same industry.
  • KRTX has a better Return On Equity (-34.58%) than 78.14% of its industry peers.
Industry RankSector Rank
ROA -32.46%
ROE -34.58%
ROIC N/A
ROA(3y)-27.82%
ROA(5y)-22.87%
ROE(3y)-29.25%
ROE(5y)-23.85%
ROIC(3y)N/A
ROIC(5y)N/A
KRTX Yearly ROA, ROE, ROICKRTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 0 -100 -200

1.3 Margins

  • KRTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KRTX Yearly Profit, Operating, Gross MarginsKRTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 -20K -40K -60K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. KRTX Health Analysis

2.1 Basic Checks

  • KRTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, KRTX has more shares outstanding
  • There is no outstanding debt for KRTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
KRTX Yearly Shares OutstandingKRTX Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M
KRTX Yearly Total Debt VS Total AssetsKRTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M 1B

2.2 Solvency

  • KRTX has an Altman-Z score of 90.95. This indicates that KRTX is financially healthy and has little risk of bankruptcy at the moment.
  • KRTX's Altman-Z score of 90.95 is amongst the best of the industry. KRTX outperforms 98.81% of its industry peers.
  • KRTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 90.95
ROIC/WACCN/A
WACC8.97%
KRTX Yearly LT Debt VS Equity VS FCFKRTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 500M 1B

2.3 Liquidity

  • A Current Ratio of 19.31 indicates that KRTX has no problem at all paying its short term obligations.
  • KRTX has a Current ratio of 19.31. This is amongst the best in the industry. KRTX outperforms 93.56% of its industry peers.
  • KRTX has a Quick Ratio of 19.31. This indicates that KRTX is financially healthy and has no problem in meeting its short term obligations.
  • KRTX has a Quick ratio of 19.31. This is amongst the best in the industry. KRTX outperforms 93.56% of its industry peers.
Industry RankSector Rank
Current Ratio 19.31
Quick Ratio 19.31
KRTX Yearly Current Assets VS Current LiabilitesKRTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. KRTX Growth Analysis

3.1 Past

  • KRTX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -34.42%.
  • Looking at the last year, KRTX shows a very negative growth in Revenue. The Revenue has decreased by -93.89% in the last year.
EPS 1Y (TTM)-34.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-35.59%
Revenue 1Y (TTM)-93.89%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

  • Based on estimates for the next years, KRTX will show a very strong growth in Earnings Per Share. The EPS will grow by 32.97% on average per year.
  • The Revenue is expected to grow by 331.85% on average over the next years. This is a very strong growth
EPS Next Y-5.2%
EPS Next 2Y13.86%
EPS Next 3Y27.79%
EPS Next 5Y32.97%
Revenue Next Year1701.02%
Revenue Next 2Y1192.99%
Revenue Next 3Y680.54%
Revenue Next 5Y331.85%

3.3 Evolution

KRTX Yearly Revenue VS EstimatesKRTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 1B 2B 3B 4B
KRTX Yearly EPS VS EstimatesKRTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 10 -10 20 30 40

More info and screens

Find the best growth stocksShow best growing peers

1

4. KRTX Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for KRTX. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for KRTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KRTX Price Earnings VS Forward Price EarningsKRTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KRTX Per share dataKRTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 20 30

4.3 Compensation for Growth

  • A more expensive valuation may be justified as KRTX's earnings are expected to grow with 27.79% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.86%
EPS Next 3Y27.79%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. KRTX Dividend Analysis

5.1 Amount

  • No dividends for KRTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

KRTX Fundamentals: All Metrics, Ratios and Statistics

KARUNA THERAPEUTICS INC

NASDAQ:KRTX (3/15/2024, 8:00:03 PM)

After market: 329.83 0 (0%)

329.83

+0.09 (+0.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-22
Earnings (Next)05-02
Inst Owners0.38%
Inst Owner Change0%
Ins Owners7.23%
Ins Owner Change0%
Market Cap12.58B
Revenue(TTM)650.00K
Net Income(TTM)-433.67M
Analysts68.7
Price Target329.12 (-0.22%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-12.15%
Min EPS beat(2)-12.95%
Max EPS beat(2)-11.34%
EPS beat(4)2
Avg EPS beat(4)-5.26%
Min EPS beat(4)-12.95%
Max EPS beat(4)2.87%
EPS beat(8)4
Avg EPS beat(8)-2.43%
EPS beat(12)7
Avg EPS beat(12)2.66%
EPS beat(16)10
Avg EPS beat(16)1.82%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.14%
PT rev (3m)21.05%
EPS NQ rev (1m)-10.81%
EPS NQ rev (3m)-9.9%
EPS NY rev (1m)-8.48%
EPS NY rev (3m)-8.48%
Revenue NQ rev (1m)-31.35%
Revenue NQ rev (3m)-31.35%
Revenue NY rev (1m)-48.2%
Revenue NY rev (3m)-50.42%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 19358.48
P/FCF N/A
P/OCF N/A
P/B 10.03
P/tB 10.03
EV/EBITDA N/A
EPS(TTM)-11.72
EYN/A
EPS(NY)-12.33
Fwd EYN/A
FCF(TTM)-10.19
FCFYN/A
OCF(TTM)-10.11
OCFYN/A
SpS0.02
BVpS32.88
TBVpS32.88
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -32.46%
ROE -34.58%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-27.82%
ROA(5y)-22.87%
ROE(3y)-29.25%
ROE(5y)-23.85%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 171.49%
Cap/Sales 448.77%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 19.31
Quick Ratio 19.31
Altman-Z 90.95
F-Score2
WACC8.97%
ROIC/WACCN/A
Cap/Depr(3y)285.44%
Cap/Depr(5y)267.27%
Cap/Sales(3y)154.33%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-34.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-35.59%
EPS Next Y-5.2%
EPS Next 2Y13.86%
EPS Next 3Y27.79%
EPS Next 5Y32.97%
Revenue 1Y (TTM)-93.89%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year1701.02%
Revenue Next 2Y1192.99%
Revenue Next 3Y680.54%
Revenue Next 5Y331.85%
EBIT growth 1Y-70.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-4.48%
EBIT Next 3Y26.73%
EBIT Next 5Y28.98%
FCF growth 1Y-69.81%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-69.21%
OCF growth 3YN/A
OCF growth 5YN/A

KARUNA THERAPEUTICS INC / KRTX Fundamental Analysis FAQ

What is the ChartMill fundamental rating of KARUNA THERAPEUTICS INC (KRTX) stock?

ChartMill assigns a fundamental rating of 3 / 10 to KRTX.


Can you provide the valuation status for KARUNA THERAPEUTICS INC?

ChartMill assigns a valuation rating of 1 / 10 to KARUNA THERAPEUTICS INC (KRTX). This can be considered as Overvalued.


Can you provide the profitability details for KARUNA THERAPEUTICS INC?

KARUNA THERAPEUTICS INC (KRTX) has a profitability rating of 1 / 10.


What is the earnings growth outlook for KARUNA THERAPEUTICS INC?

The Earnings per Share (EPS) of KARUNA THERAPEUTICS INC (KRTX) is expected to decline by -5.2% in the next year.